Reflections 5 years on from the approval of ETI therapy.

Competing Interests: PGM reports having been Chief Investigator in the Trikafta trial published in the New England Journal of Medicine 2019; receiving honoraria for lectures and presentations from Vertex, AstraZeneca, Limbic, and MedEd; and being a member of the Cystic Fibrosis Foundation (CFF) Data Safety Monitoring Board, the European Cystic Fibrosis Society Standards of Care Committee, the Australian Cystic Fibrosis Standards of Care Committee, the Australian Cystic Fibrosis Data Registry, and the Australian Bronchiectasis Registry. JLT-C reports having been site or national principal investigator on studies for 4DMT, Vertex, and Eloxx, as faculty at an institution that is part of the CFF Therapeutics Development Network; grant funding from CFF and the National Institutes of Health; payments to institution for clinical trial advising efforts from Vertex and 4DMT; travel support for participation in Board of Trustees meetings from CFF; payments for role as Chair of a data monitoring committee from AbbVie; serving as the adult patient care representative to the CFF Board of Trustees, on the CFF Clinical Research Executive Committee, Clinical Research Advisory Board, Racial Justice Working Group, as immediate past chair of the CFF Therapeutics Development Network's Sexual Health, Reproduction and Gender Research Working Group, as Co-Chair of the Heath Equity Team Science Awards study section, on the scientific advisory board for Emily's Entourage, on the American Thoracic Society Scientific Grant Review Committee, on the Respiratory Research Awards Committee, as Chair-Elect for the ATS International Conference Committee, and on the NHLBI Clinical Trials Study Section; and being a member of the International Advisory Board for The Lancet Respiratory Medicine and the Editorial Board for the Journal of Cystic Fibrosis.